

## Review Article

# Vitamin E and Leukocyte–Endothelial Cell Interactions

TOSHIKAZU YOSHIKAWA and NORIMASA YOSHIDA

### ABSTRACT

Leukocyte–endothelial cell interactions are mediated by adhesion molecules, expression of which is modulated by cytokines and chemical mediators in the early phase of inflammatory and immunologic reactions, including the development of atherosclerosis. Vitamin E is a lipid-soluble antioxidant that is present in all cell membranes at a low concentration and is reported to be an anti-atherogenic agent. Recently, it was reported that vitamin E inhibits the activation of protein kinase C and nuclear factor-kappa B (NF- $\kappa$ B). We demonstrated that vitamin E can prevent leukocyte–endothelial cell adhesion by inhibiting signal transduction involved in the surface expression of adhesion molecules by leukocytes and endothelial cells. These results suggest that vitamin E may have a protective effect against the progression of inflammation and atherosclerosis. *Antiox. Redox Signal.* 2, 821–825.

### ADHESION MOLECULES INVOLVED IN LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS

**A**DHERENCE OF POLYMORPHONUCLEAR LEUKOCYTES (PMN) to the endothelium and migration of PMN into the extravascular space are characteristic steps in the process of inflammation. PMN–endothelial cell interactions are known to be mediated by adhesion molecules that are expressed on both types of cells, and the expression of these molecules is modulated by inflammatory cytokines and lipid mediators (Springer, 1990). Among the adhesion molecules expressed on leukocytes, L-selectin mediates rolling of leukocytes along the endothelium, whereas the CD11/CD18 integrin family, which is comprised of an immunologically distinct  $\alpha$ -subunit (CD11a, CD11b, or CD11c) and a common  $\beta_2$ -subunit (CD18), plays a major role in the adhesion and transendothelial migration of PMN both *in vitro* and *in vivo* (Ton-

nesen, 1989; Carlos and Harlan, 1990). Chemotactic factor-induced adherence of PMN is mainly dependent on CD11b/CD18. Up-regulation of CD11b/CD18 has been reported to occur within a few minutes and involves receptor rearrangement or the translocation of preformed receptors from intracellular stores, similar to the up-regulation of P-selectin expression on endothelial cells (EC) (Zimmerman *et al.*, 1992; Granger and Kubes, 1994). In addition, the process of leukocyte adherence to EC involves increased surface expression of membrane glycoproteins, E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular adhesion molecule-1 (VCAM-1) on EC, which requires several hours to reach a maximal level after endothelial cell activation. After up-regulation, these molecules on EC interact with receptors on leukocytes. Specifically, E-selectin, ICAM-1, and VCAM-1 on EC interact with sialyl Lewis-X-containing molecules, CD11b/CD18, and VLA-4 integrins ( $\alpha_4\beta_1$ ), respectively,

---

First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyō-ku, Kyoto 602-8566, Japan.

on leukocytes (Springer, 1990; Zimmerman *et al.*, 1992; Granger and Kubes, 1994).

### VITAMIN E AND NEUTROPHIL-DEPENDENT ADHESION TO ENDOTHELIAL CELLS

Oxidized low-density lipoprotein (oxLDL) is an important indicator of oxidative stress as well as being a potent chemotactic agent that is involved in the infiltration of leukocytes during the early processes of atherosclerosis (Steinberg *et al.*, 1989; Lehr *et al.*, 1993). OxLDL exhibits a wide variety of potentially atherogenic properties *in vitro*, including stimulation of monocyte migration (Navab *et al.*, 1991), promotion of neutrophil and mononuclear cell adhesion to EC (Quinn *et al.*, 1987; Fröstegård *et al.*, 1991; Couffinhal *et al.*, 1993), and inhibition of endothelium-dependent vasodilation (Simon *et al.*, 1990), but there have been few reports that oxLDL induces integrin up-regulation. In a recent study (Yoshida *et al.*, 1999), we showed that oxLDL, but not native LDL, stimulates the up-regulation of CD11b/CD18 expression on PMN. We also found that lysophosphatidylcholine (lysoPC), a potent component of oxLDL and an inducer of transient ICAM-1 and VCAM-1 expression by human aortic EC (Kume *et al.*, 1992), did not induce the up-regulation of CD11b/CD18. These results suggested that a component of oxLDL other than lysoPC played a role in the up-regulation of CD11b/CD18 expression on PMN.

$\alpha$ -Tocopherol ( $\alpha$ -Toc) is a lipid-soluble vitamin and a chain-breaking tissue antioxidant that is present in all cell membranes at a low concentration and is reported to be an anti-atherogenic agent (Burton and Ingold, 1989; Janero, 1991).  $\alpha$ -Toc is also thought to be an immunomodulator, enhancing both cell-mediated and humoral immunity (Tengerdy, 1989), although the mechanism of this action has not been determined. The cytoprotective effect of  $\alpha$ -Toc is attributed to its ability to act as a scavenger of highly reactive oxygen radicals, thus stabilizing membranes against lipid peroxidation (Chow, 1991; Urano and Matsuo, 1989), and to its inhibition of protein kinase C (PKC), as shown by studies using rat brain ho-

mogenates (Mahoney and Azzi, 1988), permeabilized vascular smooth muscle cells, and neuroblastomas (Boscoboinik *et al.*, 1991). Recent studies have suggested that vitamin E supplementation may be of benefit in the prevention of coronary artery disease (Rimm *et al.*, 1993; Stampfer *et al.*, 1993; Stephens *et al.*, 1996). It has also been suggested that  $\alpha$ -Toc may act at the level of vascular cell gene expression (Faruqi *et al.*, 1994).

The effects of antioxidants on leukocyte-endothelial cell interactions involved in atherosclerosis and heart diseases have attracted considerable attention. Recently, we found that vitamin E decreased the level of CD11b/CD18 expression on human PMN monocytes induced by oxLDL, platelet-activating factor (PAF), or *N*-formyl methionyl-leucyl-phenylalanine (fMLP) (Yoshikawa *et al.*, 1998; Yoshida *et al.*, 1999; Terasawa *et al.*, 2000). An inhibitory effect of vitamin E on CD11/CD18 expression was also demonstrated in an *ex vivo* study. Using blood samples obtained from volunteers who received  $\alpha$ -Toc (600 mg/day) for 10 days, it was shown that CD11b/CD18 expression induced by fMLP or oxLDL was significantly reduced after administration of vitamin E. Also the level of CD11b/CD18 expression was inversely correlated with the serum vitamin E concentration. Furthermore, adhesion of fMLP- or oxLDL-stimulated PMN to intact EC was suppressed by  $\alpha$ -Toc (50–200  $\mu$ M) in a concentration-dependent manner.

On the other hand, vitamin E did not inhibit CD11b/CD18 up-regulation and PMN adherence induced by phorbol 12-myristate-13-acetate (PMA), a direct activator of PKC, whereas a PKC inhibitor suppressed the up-regulation of CD11b/CD18 by fMLP, oxLDL, or PMA in a concentration-dependent manner. Thus, fMLP-, oxLDL-, and PMA-induced up-regulation of CD11b/CD18 occurs via direct or indirect activation of PKC. Although  $\alpha$ -Toc did not affect PKC activity in unstimulated cells, it slightly inhibited the increase of PKC activity in response to fMLP or oxLDL stimulation, but not that caused by PMA stimulation, suggesting that  $\alpha$ -Toc tends to reduce the response of PKC to indirect stimuli. It is probable that  $\alpha$ -Toc acts on signal transduction pathways from surface receptors to PKC activation. It has been

reported that a decrease in the membrane fluidity of stimulated leukocytes can induce up-regulation of CD11b/CD18 via modulation of receptor translocation from intracellular stores (Detmers *et al.*, 1987; Vosatka *et al.*, 1988).  $\alpha$ -Toc may stabilize membrane fluidity because of its ability to act as a scavenger of reactive oxygen radicals, thus protecting membranes against lipid peroxidation (Urano and Matsuo, 1989; Chow, 1991). Further studies are needed to determine the molecular mechanisms by which  $\alpha$ -Toc inhibits up-regulation of CD11b/CD18 on activated PMN.

Neutrophil activation also triggers the functional activation of preexisting cell-surface CD11b/CD18, presumably through conformational and/or topological alternations (Buyon *et al.*, 1988). Neutrophil adhesion may also be attributed to the phosphorylated activation as well as up-regulation of CD11b/CD18 (Schleifenbaum *et al.*, 1989). Therefore, one possibility is that  $\alpha$ -Toc may prevent neutrophil adhesion by inhibiting the functional activation of constitutively expressed CD18.

In summary, the present study suggests that  $\alpha$ -Toc can block the adhesion of PMN to EC stimulated by fMLP or oxLDL, probably by modulating quantitative and/or functional changes of CD11b/CD18. Accordingly,  $\alpha$ -Toc may have a protective effect against the progression of inflammation and atherosclerosis by modulating leukocyte-dependent interactions with EC.

### VITAMIN E AND ENDOTHELIAL-DEPENDENT LEUKOCYTE ADHESION

Endothelial adhesion molecules play an important role in the rolling and adhesion of leukocytes within the circulatory system. It is well known that several cytokines, such as interleukin-1 $\beta$  (IL-1 $\beta$ ) or tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), induce the surface expression of ICAM-1 and VCAM-1 on endothelial cells through the activation of transcription factor, nuclear factor-kappa B (NF- $\kappa$ B), followed by synthesis of its mRNA (Iademarco *et al.*, 1992; Hou *et al.*, 1994). Recently, LDL and oxLDL have been shown to induce the up-regulation

of adhesion molecules on endothelial cells. In our experiments, ICAM-1 and VCAM-1 expression on oxLDL-stimulated human umbilical vein endothelial cells (HUVEC) was found to occur in the same fashion as after stimulation with IL-1 (Yoshida *et al.*, 1997; Yoshikawa *et al.*, 1998). However, LDL did not have any effect on the expression of endothelial adhesion molecules. These results suggest that oxLDL may induce almost the same signal transduction pathway for the synthesis of ICAM-1 and VCAM-1 as that stimulated by IL-1 (Yoshikawa *et al.*, 1998), but the precise mechanisms involved still need to be investigated. In addition, we found that vitamin E inhibited the synthesis of mRNA and protein for ICAM-1 and VCAM-1 by HUVEC in response to stimulation with oxLDL or IL-1 (Yoshikawa *et al.*, 1998). Previously, we showed that vitamin E inhibited the surface expression of ICAM-1 and VCAM-1 on EC exposed to IL-1 (Yoshida *et al.*, 1999). Cominacini *et al.* (1997) also reported that vitamin E and probucol decreased ICAM-1 and VCAM-1 expression on HUVEC in response to oxLDL stimulation. Recently, it has been suggested that active oxygen species are implicated in the activation of NF- $\kappa$ B, which is necessary for the expression of various adhesion molecules. Nakamura *et al.* (1998) and Erl *et al.* (1997) have reported that some forms of vitamin E inhibit NF- $\kappa$ B activation. These findings suggest that vitamin E may prevent NF- $\kappa$ B-




FIG. 1. Scheme of inhibitory effect of vitamin E on leukocyte-endothelial cell interactions. Cytokines and oxLDL induce surface expression of ICAM-1 and VCAM-1 on endothelial cells and CD11b/CD18 on leukocytes. Vitamin E inhibits leukocyte-endothelial cell adhesion by reducing up-regulation of adhesion molecules.

mediated expression of adhesion molecule mRNAs and proteins by reducing oxidative stress on EC.

In summary, the results summarized here indicate that vitamin E can reduce endothelial-dependent leukocyte adhesion by inhibiting signal transduction involved in the surface expression of ICAM-1 and VCAM-1 on EC, suggesting that vitamin E may act as an anti-inflammatory and anti-atherogenic agent (Fig. 1).

## ABBREVIATIONS

fMLP, *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine; ICAM-1, intercellular adhesion molecule-1; NF- $\kappa$ B, nuclear factor-kappa B; oxLDL, oxidized low density lipoprotein; PAF, platelet activating factor; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; PMN, polymorphonuclear leukocytes;  $\alpha$ -Toc,  $\alpha$ -Tocopherol; VCAM-1, vascular adhesion molecule-1.

## REFERENCES

- BOSCOBINIK, D., SZEWCZYK, A., HENSEY, C., and AZZI, A. (1991). Inhibition of cell proliferation by  $\alpha$ -tocopherol. *J. Biol. Chem.* **266**, 6188–6194.
- BURTON, G.W., and INGOLD, K.U. (1989). Vitamin E as an in vitro and in vivo antioxidant. *Ann. N.Y. Acad. Sci.* **570**, 7–22.
- BUYON, J.P., ABRAMSON, S.B., PHILIPS, M.R., SLADE, S.G., ROSS, G.D., WEISSMAN, G., and WINCHESTER, R.J. (1988). Dissociation between increased surface expression of gp165/95 and hemotypic neutrophil aggregation. *J. Immunol.* **140**, 3156–3160.
- CARLOS, T.M., and HARLAN, J.M. (1990). Membrane proteins involved in phagocyte adherence to endothelium. *Immunol. Rev.* **114**, 5–28.
- CHOW, C.K. (1991). Vitamin E and oxidative stress. *Free Radical Biol. Med.* **11**, 215–232.
- COMINACINI, L., GARBIN, U., PASINI, A.F., DAVOLI, A., CAMPAGNOLA, M., CONTESSI, G.B., PAS-TORINO, A.M., and CASINNO, LO V. (1997). Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. *Free. Radic. Biol. Med.* **22**, 117–127.
- COUFFINHAL, T., DUPLAA, C., LABAT, L., MOREAU, C., BIETZ, I., and BONNET, J. (1993). Effect of low density lipoprotein on monocyte adhesiveness to endothelial cells in vitro. *Atherosclerosis* **99**, 35–45.
- DETMERS, P.A., WRIGHT, S.D., OLSEN, E., KIMBALL, B., and COHN, Z.A. (1987). Aggregation of complement receptors on human neutrophils in the absence of ligand. *J. Cell. Biol.* **105**, 1137–1145.
- ERL, W., WEBER, C., WARDEMAN, C., and WEBER, P.C. (1997). Alpha-Tocopheryl succinate inhibits monocyte cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. *Am. J. Physiol.* **273**, H634–H640.
- FARUQI, R., DE LA MOTTE, C.A., and DICORLETO, P.E. (1994).  $\alpha$ -Tocopherol inhibits agonist-induced monocyte cell adhesion to cultured human endothelial cells. *J. Clin. Invest.* **94**, 592–600.
- FRÖSTEGARD, J., HÄGERSTRAND, A., GIDLIND, M., and NILSSON, J. (1991). Biologically modified LDL increases the adhesive properties of endothelial cells. *Atherosclerosis* **90**, 119–126.
- GRANGER, D.N., and KUBES, P. (1994). The microcirculation and inflammation: modulation of leukocyte-endothelial adhesion. *J. Leukocyte Biol.* **55**, 662–675.
- HOU, J., BAICHWAL, V., and CAO, Z. (1994). Regulatory elements and transcription factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1. *Proc. Natl. Acad. Sci. USA* **91**, 11641–11645.
- IADEMARCO, M.F., MCQUILLAN, J.J., ROSEN, G.D., and DEAN, D.C. (1992). Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). *J. Biol. Chem.* **267**, 16323–16329.
- JAFFE, E.A., NACHMAN, R.L., BECKER, C.G., and MINCK, C.R. (1973). Culture of human endothelial cells derived from umbilical cord veins. *J. Clin. Invest.* **52**, 2745–2756.
- JANERO, D.R. (1991). Therapeutic potential of vitamin E in the pathogenesis of spontaneous atherosclerosis. *Free Radical Biol. Med.* **11**, 129–144.
- KUME, N., CYBULSKY, M.I., and GIMBRONE, M.A. (1992). Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. *J. Clin. Invest.* **90**, 1138–1144.
- LEHR, H.A., HÜBNER, C., MENDER, M.D., and MESSER, K. (1993). Mechanism and mediators of leukocyte/endothelium interaction during atherogenesis. *Atheroscler. Rev.* **25**, 49–57.
- MAHONEY, C.W., and AZZI, A. (1988). Vitamin E inhibits protein kinase C activity. *Biochem. Biophys. Res. Commun.* **154**, 694–697.
- NAKAMURA, T., GOTO, M., MATSUMOTO, A., and TANAKA, I. (1998). Inhibition of NF- $\kappa$ B transcriptional activity by  $\alpha$ -tocopheryl succinate. *BioFactors* **7**, 21–30.
- NAVAB, M., IMES, S.S., HAMA, S.Y., HOUGH, G.P., ROSS, L.A., BORK, R.W., VALENTE, A.J., BERLINER, J.A., DRINKWATER, D.C., LAKS, H., and FOGELMAN, A.M. (1991). Monocyte transmigration induced by modification of low density lipoprotein in coculture of human aortic wall cells is due to induction of MCP-1 and is abolished by high density lipoprotein. *J. Clin. Invest.* **88**, 2039–2046.
- QUINN, M.T., PARTHASARATHY, S., FONG, L.G., and STEINBERG, D. (1987). Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherosclerosis. *Proc. Natl. Acad. Sci. USA* **84**, 2995–2998.

- RIMM, E.B., STAMPFER, M.J., ASCHERIO, A., GIOVANUCCI, E., COLDITZ, G.A., and WILLET, W.C. (1993). Vitamin E consumption and the risk of coronary disease in men. *N. Engl. J. Med.* **328**, 1450–1456.
- SCHLEIFFENBAUM, B., MOSER, R., PATARROYO, M., and FEHR, J. (1989). The cell surface glycoprotein Mac-1 (CD11b/CD18) mediates neutrophil adhesion and modulates degranulation independently of its quantitative cell surface expression. *J. Immunol.* **142**, 3537–3545.
- SIMON, B.C., CUNNINHAM, L.D., and COHEN, R.A. (1990). Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. *J. Clin. Invest.* **86**, 75–79.
- SPRINGER, T.A. (1990). Adhesion receptors of the immune system. *Nature* **346**, 425–434.
- STAMPFER, M.J., HENNEKENS, C.H., MANSON, J.E., COLDITZ, G.A., ROSNER, G., and WILLET, W.C. (1993). Vitamin E consumption and the risk of coronary disease in women. *N. Engl. J. Med.* **328**, 1444–1449.
- STEINBERG, D., PARTHASARATHY, S., CAREW, T.E., KHOO, J.C., and WITZTUM, J.L. (1989). Beyond cholesterol: modification of low density lipoprotein that increase its atherogenicity. *N. Engl. J. Med.* **320**, 915–924.
- STEPHENS, N.G., PARSONS, A., SCHUFIELD, P.M., KELLY, F., CHEESEMAN, K., MITCHINSON, M.J., and BROWN, M.J. (1996). Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* **347**, 781–786.
- TENGERDY, R.P. (1989). Vitamin E, immune response, and disease resistance. *Ann. N.Y. Acad. Sci.* **570**, 335–344.
- TERASAWA, M., MANABE, H., YOSHIDA, N., UEMURA, M., SUGIMOTO, N., NAITO, Y., YOSHIKAWA, T., KONDO, M. (2000).  $\alpha$ -Tocopherol protects against monocyte Mac-1 (CD11b/CD18) expression and Mac-1-dependent adhesion to endothelial cells induced by oxidized low density lipoprotein. *BioFactors* (in press).
- TONNESEN, M.G. (1989). Neutrophil-endothelial cell interactions: mechanisms of neutrophil adherence to vascular endothelium. *J. Invest. Dermatol.* **93**, 53S–58S.
- URANO, S., and MATSUO, M. (1989). Membrane-stabilizing effect of vitamin E. *Ann. N.Y. Acad. Sci.* **570**, 524–526.
- VOSATKA, A.H., DETMERS, P.A., GÖTZE, O., SILVERSTEIN, S.C., and WRIGHT, S.D. (1988). Clustering of ligand on the surface of a particle enhances adhesion to receptor-bearing cells. *J. Biol. Chem.* **263**, 17822–17827.
- YOSHIDA, N., GRANGER, D.N., ANDERSON, D.C., ROTHLEIN, R., LANE, C., and KVIETYS, P.R. (1992). Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. *Am. J. Physiol.* **262**, H1891–H1898.
- YOSHIDA, N., YOSHIKAWA, T., NAKAMURA, Y., SAKAMOTO, K., TAKENAKA, S., BOKU, Y., KASSAI, K., and KONDO, M. (1997). Interactions of neutrophils and endothelial cells under low flow conditions *in vitro*. *Shock* **8**, 125–130.
- YOSHIDA, N., YOSHIKAWA, T., MANABE, H., TERASAWA, Y., KONDO, M., NOGUCHI, N., and NIKI, E. (1999). Vitamin E protects against polymorphonuclear leukocyte-dependent adhesion to endothelial cells. *J. Leukoc. Biol.* **65**, 757–763.
- YOSHIDA, N., MANABE, H., TERASAWA, Y., NISHIMURA, H., ENJO, F., NISHINO, H., and YOSHIKAWA, T. (2000). Inhibitory effects of vitamin E on endothelial-dependent adhesive interactions with leukocytes induced by oxidized low density lipoprotein. *BioFactors* (in press).
- YOSHIKAWA, T., YOSHIDA, N., MANABE, H., TERASAWA, Y., TAKEMURA, T., and KONDO, M. (1998).  $\alpha$ -Tocopherol protects against expression of adhesion molecules on neutrophils and endothelial cells. *BioFactors* **7**, 15–19.
- ZIMMERMAN, G.A., PRESCOTT, S.M., and MCINTYRE, T.M. (1992). Endothelial cell interactions with granulocytes: tethering and signaling molecules. *Immunol. Today* **13**, 93–100.

Address reprint requests to:

Dr. Norimasa Yoshida

First Department of Internal Medicine

Kyoto Prefectural University of Medicine

Kawaramachi-Hirokoji, Kamigyo-ku

Kyoto 602-8566, Japan

E-mail: nyoshida@koto.kpu-m.ac.jp

Received for publication March 31, 2000; accepted May 31, 2000.

**This article has been cited by:**

1. Paulette Yamada, Fabiano Amorim, Pope Moseley, Suzanne Schneider. 2008. Heat Shock Protein 72 Response to Exercise in Humans. *Sports Medicine* **38**:9, 715-733. [[CrossRef](#)]
2. Graziano Riccioni, Tonino Bucciarelli, Barbara Mancini, Carmine Di Ilio, Valerie Capra, Nicolantonio D'Orazio. 2007. The role of the antioxidant vitamin supplementation in the prevention of cardiovascular diseases. *Expert Opinion on Investigational Drugs* **16**:1, 25-32. [[CrossRef](#)]
3. Margarita L. Alexandrova, Petyo G. BochevOxidative stress in stroke 313-368. [[CrossRef](#)]
4. Graziano Riccioni, Nicolantonio D'Orazio. 2005. The role of selenium, zinc and antioxidant vitamin supplementation in the treatment of bronchial asthma: adjuvant therapy or not?. *Expert Opinion on Investigational Drugs* **14**:9, 1145-1155. [[CrossRef](#)]
5. M ALEXANDROVA, P BOCHEV. 2005. Oxidative stress during the chronic phase after stroke. *Free Radical Biology and Medicine* **39**:3, 297-316. [[CrossRef](#)]
6. M.-T. Huang, G. Ghai, C.-T. Ho. 2004. Inflammatory Process and Molecular Targets for Antiinflammatory Nutraceuticals. *Comprehensive Reviews in Food Science and Food Safety* **3**:4, 127-139. [[CrossRef](#)]
7. I. Politis, A. Voudouri, I. Bizelis, G. Zervas. 2003. The effect of various vitamin E derivatives on the urokinase-plasminogen activator system of ovine macrophages and neutrophils. *British Journal of Nutrition* **89**:02, 259. [[CrossRef](#)]
8. Peter Stenvinkel, Anders Alvestrand. 2002. Review Articles: Inflammation in End-stage Renal Disease: Sources, Consequences, and Therapy. *Seminars in Dialysis* **15**:5, 329-337. [[CrossRef](#)]
9. Becky Kendall, Roger Eston. 2002. Exercise-Induced Muscle Damage and the Potential Protective Role of Estrogen. *Sports Medicine* **32**:2, 103-123. [[CrossRef](#)]